ES2882880T3 - Procedimiento para tratar enfermedades intestinales que presentan al menos un componente inflamatorio - Google Patents

Procedimiento para tratar enfermedades intestinales que presentan al menos un componente inflamatorio Download PDF

Info

Publication number
ES2882880T3
ES2882880T3 ES13704767T ES13704767T ES2882880T3 ES 2882880 T3 ES2882880 T3 ES 2882880T3 ES 13704767 T ES13704767 T ES 13704767T ES 13704767 T ES13704767 T ES 13704767T ES 2882880 T3 ES2882880 T3 ES 2882880T3
Authority
ES
Spain
Prior art keywords
composition
patient
budesonide
administered
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13704767T
Other languages
English (en)
Spanish (es)
Inventor
Luigi Moro
Gerald Thomas Proehl
Wendell Wierenga
Michael Fangching Huang
Ii Emerson David Ballard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Santarus Inc
Original Assignee
Cosmo Technologies Ltd
Santarus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd, Santarus Inc filed Critical Cosmo Technologies Ltd
Application granted granted Critical
Publication of ES2882880T3 publication Critical patent/ES2882880T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13704767T 2012-02-13 2013-02-13 Procedimiento para tratar enfermedades intestinales que presentan al menos un componente inflamatorio Active ES2882880T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598308P 2012-02-13 2012-02-13
PCT/EP2013/052838 WO2013120881A1 (en) 2012-02-13 2013-02-13 Method for treating intestinal diseases presenting at least one inflammatory component

Publications (1)

Publication Number Publication Date
ES2882880T3 true ES2882880T3 (es) 2021-12-03

Family

ID=47722264

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13704767T Active ES2882880T3 (es) 2012-02-13 2013-02-13 Procedimiento para tratar enfermedades intestinales que presentan al menos un componente inflamatorio

Country Status (15)

Country Link
US (5) US20130209559A1 (enExample)
EP (1) EP2814495B1 (enExample)
JP (2) JP2015506999A (enExample)
CN (2) CN104220076A (enExample)
AU (1) AU2013220464A1 (enExample)
BR (1) BR112014020095A8 (enExample)
CA (1) CA2864065A1 (enExample)
DK (1) DK2814495T3 (enExample)
ES (1) ES2882880T3 (enExample)
HK (1) HK1204927A1 (enExample)
IL (1) IL234054A0 (enExample)
IN (1) IN2014DN06662A (enExample)
PT (1) PT2814495T (enExample)
RU (1) RU2649807C2 (enExample)
WO (1) WO2013120881A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2974864B1 (fr) * 2011-05-04 2016-05-27 Snecma Rotor de turbomachine avec moyen de retenue axiale des aubes
AU2014262139A1 (en) * 2013-05-01 2015-11-26 3 Electric Sheep Pty Ltd Event notification systems and methods
WO2015071812A1 (en) * 2013-11-18 2015-05-21 Wockhardt Limited Solid oral modified-release composition comprising budesonide or salt thereof
US10327034B2 (en) * 2014-03-27 2019-06-18 Tvu Networks Corporation Methods, apparatus and systems for exchange of video content
EP4431094A3 (en) 2017-11-10 2024-11-20 Cosmo Technologies Ltd. Oral rifamycin sv compositions
EP3501496A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Liquid delivery composition
CN110585164A (zh) * 2019-10-08 2019-12-20 苏州弘森药业股份有限公司 一种艾司奥美拉唑镁碳酸氢钠胶囊的制作方法
WO2025002033A1 (zh) * 2023-06-26 2025-01-02 湖南慧泽生物医药科技有限公司 一种含皮质类固醇的药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
DE19849737A1 (de) * 1998-10-28 2000-05-04 Falk Pharma Gmbh Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2004087109A1 (ja) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
WO2008033124A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
EP2392321A1 (en) * 2007-06-13 2011-12-07 Jay Pravda Combined composition for rectal administration for the treatment of inflammatory bowel disease
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD

Also Published As

Publication number Publication date
IL234054A0 (en) 2014-09-30
BR112014020095A2 (enExample) 2017-06-20
EP2814495B1 (en) 2021-07-07
US20130209559A1 (en) 2013-08-15
EP2814495A1 (en) 2014-12-24
JP2017210476A (ja) 2017-11-30
US20140187517A1 (en) 2014-07-03
RU2014137128A (ru) 2016-04-10
WO2013120881A1 (en) 2013-08-22
HK1204927A1 (en) 2015-12-11
IN2014DN06662A (enExample) 2015-05-22
PT2814495T (pt) 2021-08-19
RU2649807C2 (ru) 2018-04-04
US20150017239A1 (en) 2015-01-15
AU2013220464A1 (en) 2014-09-04
BR112014020095A8 (pt) 2017-07-11
JP6472063B2 (ja) 2019-02-20
CN110693890A (zh) 2020-01-17
JP2015506999A (ja) 2015-03-05
US20200163888A1 (en) 2020-05-28
DK2814495T3 (da) 2021-08-23
US20130225537A1 (en) 2013-08-29
CA2864065A1 (en) 2013-08-22
CN104220076A (zh) 2014-12-17

Similar Documents

Publication Publication Date Title
AU776099B2 (en) Oral solid pharmaceutical formulations with ph-dependent multiphasic release
JP6472063B2 (ja) 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
ES2649063T3 (es) Formulaciones farmacéuticas que contienen rifaximina, procedimientos para su obtención y método de tratamiento de la enfermedad intestinal
ES2958616T3 (es) Formulaciones farmacéuticas de floroglucinol y trimetilfloroglucinol
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
ES2922749T3 (es) Composiciones de sabor agradable que incluyen fenilbutirato de sodio y sus usos
JP6566638B2 (ja) メサラミンの放出制御固形製剤
CN102369000A (zh) 包含一种或多种富马酸酯的药用组合物
BR112012021275B1 (pt) Formulação compreendendo um adsorvente misturado com carragenina, para entrega oral e liberação controlada de adsorventes no intestino, e, uso de uma formulação
ES2654945T3 (es) Formulaciones orales de carotenoides trans bipolares
BRPI0612921A2 (pt) composições farmacêuticas de um esteróide neuroativo e métodos de uso do mesmo
ES2529455T3 (es) Sistema de administración de fármacos por dosis controladas
ES2408343A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
ES2386922T3 (es) Composiciones farmacéuticas para la administración oral de la heparina o de los derivados de la misma
KR20170056574A (ko) 알펠리십을 포함하는 제약 조성물
ES2605650T3 (es) Formulación farmacéutica que contiene fosfatidilcolina para el tratamiento de la colitis ulcerativa
ES2908924T3 (es) Composiciones orales sólidas de liberación lenta
ES2537704T3 (es) Pellets farmacéuticos administrables por vía oral de factor de crecimiento epidérmico
JP7673210B2 (ja) 皮膚放射線傷害の予防及び治療のための組成物及び方法
Kienzler et al. Diclofenac potassium 12.5 mg liquid capsules: earlier and higher exposure to diclofenac
ES2863402T3 (es) Combinación de plantas oficinales y su uso en el tratamiento y/o prevención de trastornos del sueño
Egan et al. HIGHER TROUGH GOLIMUMAB LEVELS ARE ASSOCIATED WITH EARLY CLINICAL AND BIOCHEMICAL RESPONSE; EARLY RESULTS OF THE GOAL-ARC STUDY
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療
BR112015006642B1 (pt) Composição farmacêutica de liberação prolongada compreendendo metadoxina e prednisona
EA049553B1 (ru) Новые полиморфные формы метопимазина